A deluge of generic weight-loss drugs are forecast to flow soon after when patents of semaglutide, used to make Novos weight loss medicine, start to expire in 2026
As the supplement industry grows, with innovations in packaging services and custom formulas, its tempting to pin your hopes on a pill
Mounjaro (also known as tirzepatide) is a once-weekly injection that treats type 2 diabetes and offers weight management support
The study isnt yet peer-reviewed, but it appears to show retatrutide leaving other GLP-1s in the dust: The highest dose made patients lose an average of 28% of their body mass after 80 weeks, running nearly a full lap around the highest dose of Novo Nordisks Wegovy (~15% weight loss after 68 weeks)
It is one of the most widely used GLP-1 medications for chronic weight management in adults and adolescents, and it is available in two forms: an injection and a pill
References Witschi, A., Reddy, S., Stofer, B